Participated · Seed · Mar 2026

Founded in 2019, Canada-based Dispersa has developed BioEterna®, a synthetic-biology and precision-fermentation platform that feeds waste oils and sugars to microbes, producing PuraSurf®, the world’s first 100% waste-derived biosurfactant. The ingredient can slot into cleaners, detergents, shampoos, cosmetics and other formulations traditionally reliant on fossil or palm inputs. With facilities in Laval, Québec and biomanufacturing partners in Nova Scotia, the company is nearing 100-tonnes-per-year production capacity and is preparing to fulfill commercial orders across North America. Dispersa’s circular model simultaneously diverts food waste from landfills and lowers the carbon and biodiversity impacts tied to conventional surfactants. The startup has raised more than $13 million CAD to date, enabling its transition from lab proof-of-concept to commercial-scale manufacturing. Seed funding is being deployed to expand production, accelerate customer integrations and advance additional waste-to-chemical product lines.

Participated · Series A · May 2025

Exterra Carbon Solutions develops proprietary processes (LOW™ and ROC™) to convert legacy mining waste into low‑carbon metal oxides, valuable by-products, and permanently mineralize CO2. The company’s commercialization strategy centers on its upcoming Hub I project, scheduled to begin construction in 2027 in Quebec, which will process over 300,000 tonnes of asbestos mine tailings annually and fully destroy remaining asbestos fibres. Exterra has de-risked its technologies through pre-commercial pilot operations in Val‑des‑Sources, Quebec. After Hub I’s inauguration, the company plans to integrate its technologies into larger-scale mining and mineral-processing applications internationally, including acid recycling and emissions mineralization. The business is led by CEO Olivier Dufresne and intends to use newly raised funds to accelerate integration of the mining industry into the circular economy. Financially, the company closed a CAD$20M Series A and has raised CAD$32M in total to date.

Led · Series C · Jul 2024

H55 develops certified electric propulsion systems, battery packs and energy management solutions for aviation. The company raised CHF65M in Series C financing to fund expansion and product work. It plans a North American expansion that includes manufacturing at a Montreal facility and engineering customization with partners such as Pratt & Whitney Canada, CAE and Harbour Air. H55 finalized all EASA certification requirements for its battery packs and had its Energy Storage System Compliance Check List approved in March 2024. Rigorous testing validated the safety and performance of the battery pack, positioning H55 to support aircraft integrations. The company expects its battery packs to be ready for integration into CS-23 aircraft starting early in 2025. H55 provides electric propulsion systems designed to enhance sustainability, efficiency, and safety in the aerospace sector. The company develops electric and hybrid propulsion solutions and battery systems aimed at the emerging electric aviation market. Led by CEO Martin Larose and Executive Chairman André Borschberg, H55 is commercializing its technologies and pursuing Type Certification (TC) by 2024. The firm plans to expand manufacturing, including a new factory in Montreal, move to semi- and automated production in its Swiss and Canadian facilities, and open a subsidiary in Toulouse, France. The CHF 45M Series C financing will be used to accelerate commercialization and support these infrastructure investments. H55 develops certified electric propulsion and battery management solutions, focusing on the entire propulsion chain from energy source and management through thrust, power and pilot interface. The company has developed a certifiable modular battery system intended for use in new electric aircraft concepts and designs. Its roadmap starts with electric flight trainers and progresses to propulsion systems for 4–6 seaters, commuter aeroplanes and VTOL aircraft. H55 plans its first product to be used by aircraft manufacturers to provide electric flight trainers to pilot schools by 2022. The company was created in 2017 as a technological spin‑off from Solar Impulse by André Borschberg, Sébastien Demont and Gregory Blatt. The recent CHF20 million financing, including a Canton of Valais grant, will fund expansion of operations and the engineering team and support certification efforts.

Led · Equity · Apr 2024

Neurenati Therapeutics is a Québec-based biotech focused on rare pediatric diseases, with a lead program targeting Hirschsprung disease (HD). Its lead asset, NEU-001, is a first-in-class, once-in-a-lifetime intrarectal combination therapy using a neurotrophic growth factor intended to regenerate the enteric nervous system and restore gastrointestinal motility in newborns. The company aims to eliminate the need for pull-through surgery, the current invasive and non-curative standard of care. NEU-001 has received U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation, which may provide seven years of marketing exclusivity, user-fee exemptions, tax credits, and potential eligibility for a Rare Pediatric Disease Priority Review Voucher upon approval. Neurenati is completing IND-enabling preclinical studies with plans to initiate a first-in-human trial by the end of H1 2026 and is proceeding with cGMP production of the growth factor. The company recently closed a $1.7M extended seed financing to fund development and expand its core team, and appointed Dr. Meriam Kabbaj as Chief Development Officer to lead R&D and regulatory strategy. Neurenati Therapeutics is a Québec-based biotech focused on developing therapies for rare pediatric diseases, with its lead program NEU-001 targeting Hirschsprung disease. NEU-001 is positioned as a growth-factor therapy intended to treat newborns with HSCR and avert the need for surgery and associated complications. The company says HSCR affects roughly 1,300 newborns in North America each year. Recent financing is intended to fund development of an optimal formulation and to accelerate progress toward clinical trials. Neurenati targets filing a clinical trial application in Canada and the United States by the end of 2025. The company is also actively looking for additional technologies in the rare-disease pediatric space. Neurenati Therapeutics is a Québec-based biotech developing NEU-001, a first-in-class growth-factor therapy intended to promote enteric nerve cell formation and treat Hirschsprung disease (HSCR) in newborns. The company aims to offer a non-surgical alternative to current surgical treatment and to reduce lifelong complications such as enterocolitis; HSCR affects roughly 100 Canadian newborns each year. Since 2021 Neurenati holds exclusive worldwide rights to an innovative growth factor technology developed by Nicolas Pilon and Rodolphe Soret at UQAM, and both scientists remain actively involved in the company’s strategy and activities. Neurenati closed a $1.2M seed financing from Genson Capital and has secured a CQDM-SynergiQc grant; Axelys and Quebec’s MEIE provided early support. The seed round remains open and the company expects additional funding during 2024. Neurenati plans to file an IND application for NEU-001 in the second half of 2025 and has added Alexandre Lebeaut as an independent director to its board.

Participated · Equity · Jul 2023

BrainBox AI develops autonomous building technology that uses deep learning and cloud-based algorithms to optimize HVAC and reduce energy consumption. Its AI has been installed in over 700 commercial buildings across 20 countries. This year the company launched an autonomous decarbonization solution targeting the 38% of global greenhouse gases emitted by buildings. The company says recent funding will increase the scope and global scalability of its technology. Financial details in the articles note a $30 million fundraising close and a $10 million investment from a leading European insurance and asset manager. BrainBox supports real estate clients across office, hotel, retail, grocery and airport sectors and positions its tech as a 24/7 self-operating solution requiring no human intervention. BrainBox AI develops deep learning–based autonomous building technology that optimizes HVAC systems to cut energy costs and carbon emissions at commercial sites. Its platform claims up to 25% energy cost savings and up to 40% reductions in buildings' carbon footprints while improving occupant comfort. The company sells solutions across sectors including offices, hotels, retail, grocery stores, and airports, and recently launched a product specifically for multi-site retailers. BrainBox AI plans to expand global deployment by increasing automation of its models and strengthening cloud computing infrastructure. The company works with research partners including NREL, IVADO, MILA and McGill University to advance its technology. BrainBox AI was founded in 2017, is headquartered in Montreal, and employs over 150 people. BrainBox AI develops AI-driven HVAC and autonomous building technology that optimizes energy use, occupant comfort, and carbon emissions for commercial real estate owners. The company reports energy cost savings up to 25% and carbon footprint reductions up to 40%. Its technology has been installed in over 100 million square feet across 70 cities and more than 20 countries, and this year it added installations in over 180 buildings and five additional countries, including deployments in New York City and Milan. BrainBox AI works with clients across offices, hotels, retail, grocery stores and airports, and partners with research institutions including NREL, IVADO, MILA and McGill University. Headquartered in Montreal, the company has a workforce of over 150 employees and is positioning its product for continued international expansion. BrainBox AI combines deep learning, cloud-based computing and autonomous decision making to enable HVAC systems to operate autonomously and in real time. Its solution can generate up to a 25% reduction in total energy costs, a 20–40% reduction in carbon footprint and a 60% increase in occupant comfort. The company has commercial traction: in the 11 months since its May 2019 market launch it installed its self-learning technology in over 15 million square feet across 15 cities on three continents. BrainBox AI supports real estate clients across sectors including offices, airports, hotels, multi-residential, long-term care, grocery and retail. The company has a workforce of over 50 employees and positions its product as a no-capex, minimally disruptive way for building owners to cut energy costs. The recent fundraise will be used to further deploy the technology across North America and expand into additional markets.